Name

Royal Emerald Pharmaceuticals

Legal name

Royal Emerald Pharmaceuticals

Website

https://royalemeraldrx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Desert Hot Springs

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical cannabis medicines: Royal Emerald Pharmaceuticals generates revenue through the production and sale of federally compliant THC and CBD medicines. The company operates a high-tech cannabis cultivation and medical research facility to produce pharmaceutical-grade cannabis products for veterans and first responders. Revenue model based on product sales with future international and cross-state distribution capabilities.

Go-to-market motion1 record

Distribution channels2 records

Core offering

Royal Emerald Pharmaceuticals is a DEA-registered pharmaceutical manufacturer that produces federally compliant THC and CBD medicines at a high-tech cultivation and medical research facility in Desert Hot Springs, California. The company's product portfolio is targeted at veterans and first responders dealing with conditions such as PTSD and related health consequences, with regulatory clearance to ship cannabis-based medicines across U.S. state lines and internationally. The company focuses specifically on non-addictive alternate cannabinoid medicines.

Product overview

Royal Emerald Pharmaceuticals operates as a DEA-registered specialty pharmaceutical company developing a portfolio of federally compliant cannabinoid-based medicines. The company is establishing a high-tech cannabis cultivation and medical research center in Desert Hot Springs, California, to produce THC and CBD medicines specifically designed for veterans and first responders. The product portfolio consists of two core pharmaceutical offerings: federally compliant THC medicines and federally compliant CBD medicines, both intended for medical use with capabilities for interstate and international distribution.

Differentiator

Problem solved

Functional benefit

Products and services

• Federally Compliant THC Medicines DEA-registered pharmaceutical products containing tetrahydrocannabinol (THC), manufactured to meet federal controlled-substance compliance standards and qualified for interstate and international distribution. Targeted at veterans and first responders requiring federally compliant cannabis-based medical treatment.
• Federally Compliant CBD Medicines Cannabidiol (CBD)-based pharmaceutical products manufactured under DEA-registered, pharmaceutical-grade conditions to ensure federal regulatory compliance. Designed for veterans and first responders, with capability for cross-state and international shipping.

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Aurora Cannabis: Aurora Cannabis is a major global cannabis producer with a strong medical cannabis segment serving patient populations. Comparable as a large-scale cannabis cultivator/manufacturer with medical-channel focus and international distribution ambitions.
• Columbia Care: Columbia Care operates a multi-state cannabis cultivation and dispensary network with a strong medical cannabis segment. Comparable as a vertically integrated cannabis operator serving patient populations with pharmaceutical-grade products.
• Cronos Group: Cronos Group is a global cannabis company with pharmaceutical and consumer product lines. Comparable as a federally regulated (Canadian-listed) cannabis operator pursuing pharmaceutical-grade cannabinoid production.
• Canopy Growth: Canopy Growth operates a broad cannabis portfolio including medical/pharmaceutical channels across multiple jurisdictions. Comparable as a federally compliant-leaning cannabis producer with established medical research and distribution capabilities.
• Tilray Brands: Tilray is a large diversified cannabis company with pharmaceutical-grade production capabilities and a medical cannabis portfolio targeting patient populations. Comparable as a scaled cannabis pharmaceutical operator with regulatory infrastructure and cross-jurisdiction distribution.

Direct peers

• Charlotte's Web Holdings: Charlotte's Web is a leading CBD wellness brand producing hemp-derived cannabinoid products. Comparable to Royal Emerald's federally compliant CBD medicine product as a wellness-positioned CBD manufacturer.
• GW Pharmaceuticals (Jazz Pharmaceuticals): GW Pharmaceuticals developed Epidiolex, the first FDA-approved CBD pharmaceutical, and was acquired by Jazz Pharmaceuticals. Most directly comparable to Royal Emerald as a DEA-registered, FDA-pathway cannabis pharmaceutical company producing cannabinoid-based prescription medicines.
• Medical Marijuana Inc. Medical Marijuana Inc. is a CBD/hemp wellness company focused on cannabinoid-based health products. Comparable to Royal Emerald's CBD medicine line as a non-THC-heavy cannabinoid wellness manufacturer with distribution ambitions.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat1 record

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/royalemerald_rx
• LinkedInlinkedin.com/company/royal-emerald-pharmaceutical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Royal Emerald Pharmaceuticals